Compare ATPC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATPC | ANL |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Malaysia | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.0M | 52.0M |
| IPO Year | N/A | 2023 |
| Metric | ATPC | ANL |
|---|---|---|
| Price | $1.31 | $1.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 38.3K | 11.2K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,484,905.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.66 | N/A |
| 52 Week Low | $0.90 | $1.10 |
| 52 Week High | $2.93 | $2.99 |
| Indicator | ATPC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 40.01 |
| Support Level | $1.19 | $1.32 |
| Resistance Level | $1.34 | $1.55 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 48.15 | 23.19 |
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.